



Diet-induced NASH mouse models associated with metabolic syndrome

- Unique diet-induced mouse models of non-alcoholic steatohepatitis (NASH)
- physiopathological context


Unique proprietary diet-induced animal models that enables pharmacological studies targeting NASH or fibrosis, in obesity and insulin resistance context

The diet-induced DINTM NASH *in vivo* package features:


- Mouse models to study NASH or fibrosis, associated with metabolic syndrome
- Allows to study mechanisms involved in NAFLD progression
- Predictive model: similar to human situation where the diet plays a major role in the development of NAFLD

ANIMAL MODEL


- Background strain/gender: C57BL/6J mice, male
- In house "Diet-Induced NASH" (DIN™): High Fat +cholesterol +
- Reference compounds: ezetimibe, pentoxifyllin and telmisartan
- Experimental design:



PATHOPHYSIOLOGICAL FEATURES




LIVER STEATOSIS (HE staining)



LIVER INJURIES

Plasma biomarker




*p<0.05, **p<0.01, ***p<0.001 vs. control diet, #p<0.05 #p<0.01 ###p<0.001 vs. DIN, qq<0.01 vs. DIN without ezetimibe group


Inflammation (qPCR) Fibrosis (qPCR) 40 35 30 25 20 15 Collagen 1α1 Week 17 Week 6

PROGRESSION TO FIBROSIS: DIN + Low DOSE CCL





Steatosis (Triglycerides)



END-POINTS

- Anatomopathology (histology, immunohistology)
- Plasma and liver biomarkers:
 - lipids, inflammation
 - liver enzymes
 - gene expression quantification (qPCR): standard biomarkers and others on request

REFERENCES

Dubuquoy C et al. Effects of pharmacological compounds on in vivo models of NAFLD associated to metabolic syndrome. SFD, 2014.

Sulpice T. et al. Prevention of liver damages by targeting different physiological mechanisms in a new murine NASH model associated with metabolic syndrome. World Diabetes Congress, 2013.



